In a remarkable medical breakthrough, an 11-year-old girl from North Acton, London, has become the first patient in the UK to undergo an innovative gene therapy aimed at halting the progression of her rare genetic condition, Bardet-Biedl syndrome (BBS), which threatens her sight. Catherine L’Estrange recently received this pioneering treatment, which involves injecting a healthy gene directly into the eye, and her family remains optimistic about the potential to preserve her vision and enable her to continue enjoying her favourite pastime—reading.
A Leap Forward in Gene Therapy
Catherine’s journey began with her diagnosis of BBS at just a few weeks old. This condition, which affects an estimated one in 100,000 births in the UK, is caused by mutations in one of 20 genes and typically leads to significant visual impairment by late adolescence. Symptoms also include kidney complications, obesity, learning difficulties, and physical anomalies such as extra fingers or toes.
The gene therapy Catherine received, developed by biotechnology firm MeiraGTx, is designed specifically for those with a mutation in the BBS10 gene, one of the most prevalent in BBS cases. Conducted at St Helier Hospital, the procedure involved a delicate hour-long operation where surgeons removed the jelly-like substance from Catherine’s eye and injected the healthy gene into the retina, the light-sensitive tissue at the back of the eye. This innovative approach aims to preserve dying retinal cells, potentially stabilising or even improving vision.
Family’s Journey and Hopes for the Future
Catherine’s father, Reverend Timothy L’Estrange, expressed gratitude for the early diagnosis that allowed the family to prepare for the challenges ahead. He noted that while most children with BBS are diagnosed much later, Catherine’s condition was identified early enough for them to develop strategies to support her independence and resilience as her vision deteriorated over the years.
“We were previously led to believe that gene therapy was a distant hope, likely arriving only after Catherine had lost her sight entirely,” he shared. “When we heard about this treatment becoming available, we were both surprised and overjoyed that she would be among the first in the world to receive it.”
Catherine’s surgery was particularly significant, as she is only the second person globally to undergo this treatment, following a 17-year-old girl from Canada who received the same procedure last year. The Canadian girl’s family has since lauded the treatment, describing it as a precious chance to preserve their daughter’s vision.
Monitoring Progress and Future Prospects
Currently, only one of Catherine’s eyes has been treated, and the medical team is closely monitoring her progress. Post-surgery follow-ups involve a series of vision tests, including reading charts and identifying colour shades. Early feedback from patients who have undergone similar treatments has been encouraging, with some reporting improved vision in low-light conditions. However, experts caution that it may take years to fully understand the long-term effects of this groundbreaking therapy.
Neruban Kumaran, the consultant eye surgeon at Epsom and St Helier University Hospitals NHS Trust, stated, “The hope is that we can either stabilise or improve vision, but it’s important to manage expectations. This treatment does not promise perfect vision, but it may provide significant improvements for these children’s quality of life.”
Why it Matters
The implications of Catherine’s treatment extend far beyond her individual case. It represents a significant advancement in the fight against childhood blindness linked to genetic disorders. For families facing the daunting prospect of losing their children’s vision, this therapy offers a glimmer of hope. The potential to preserve sight not only enhances the children’s independence but also alleviates the emotional burden that accompanies such conditions. As more children become eligible for this pioneering treatment, the medical community stands poised to make a lasting impact on the lives of those affected by BBS and similar genetic disorders, redefining their futures.